TY - JOUR
T1 - Impact of metabolic syndrome on the long-term survival of patients with acute myocardial infarction - Potential association with C-reactive protein
AU - Takeno, Masayoshi
AU - Yasuda, Satoshi
AU - Otsuka, Yoritaka
AU - Morii, Isao
AU - Kawamura, Atsushi
AU - Yano, Katsusuke
AU - Miyazaki, Shunichi
PY - 2008
Y1 - 2008
N2 - Background: Population-based cohort studies demonstrate that metabolic syndrome (MeS) is associated with increased risk for cardiovascular diseases and related mortalities. The present study was designed to investigate the prognostic impact of MeS in patients with acute myocardial infarction (AMI). Methods and Results: The study group was 461 AMI patients without a history of previous myocardial infarction. On the basis of the National Cholesterol Education Program Adult Treatment Panel III criteria, MeS was defined having at least 3 of the following 5 conditions: dysglycemia (impaired fasting glucose, current use of insulin or oral hypoglycemic drugs), hypertriglyceridemia, low high-density lipoprotein-cholesterol level, hypertension and obesity. The prevalence of MeS was 37% (n=172). C-reactive protein (CRP) levels increased with the increase in the number of conditions of MeS. During follow-up at a median of 17.6 months, the incidence of major adverse cardiovascular events (MACE) was significantly different between patients with and without MeS. Furthermore, after adjustment of predictive factors (age, sex, Killip class, multivessel coronary artery disease, low ejection fraction and high CRP level), MeS was an independent risk factor for MACE. Conclusions: In patients with AMI, MeS is associated with systemic inflammation and is an important predictor for MACE, which suggests the need for early identification and medical intervention for secondary prevention of MeS.
AB - Background: Population-based cohort studies demonstrate that metabolic syndrome (MeS) is associated with increased risk for cardiovascular diseases and related mortalities. The present study was designed to investigate the prognostic impact of MeS in patients with acute myocardial infarction (AMI). Methods and Results: The study group was 461 AMI patients without a history of previous myocardial infarction. On the basis of the National Cholesterol Education Program Adult Treatment Panel III criteria, MeS was defined having at least 3 of the following 5 conditions: dysglycemia (impaired fasting glucose, current use of insulin or oral hypoglycemic drugs), hypertriglyceridemia, low high-density lipoprotein-cholesterol level, hypertension and obesity. The prevalence of MeS was 37% (n=172). C-reactive protein (CRP) levels increased with the increase in the number of conditions of MeS. During follow-up at a median of 17.6 months, the incidence of major adverse cardiovascular events (MACE) was significantly different between patients with and without MeS. Furthermore, after adjustment of predictive factors (age, sex, Killip class, multivessel coronary artery disease, low ejection fraction and high CRP level), MeS was an independent risk factor for MACE. Conclusions: In patients with AMI, MeS is associated with systemic inflammation and is an important predictor for MACE, which suggests the need for early identification and medical intervention for secondary prevention of MeS.
KW - Glucose
KW - Inflammation
KW - Metabolic syndrome
KW - Myocardial infarction
UR - http://www.scopus.com/inward/record.url?scp=42649091134&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=42649091134&partnerID=8YFLogxK
U2 - 10.1253/circj.72.415
DO - 10.1253/circj.72.415
M3 - Article
C2 - 18296838
AN - SCOPUS:42649091134
VL - 72
SP - 415
EP - 419
JO - Circulation Journal
JF - Circulation Journal
SN - 1346-9843
IS - 3
ER -